Heller W, Gallimore M J, Hoffmeister H E
Department of Thoracic, Heart and Cardiovascular Surgery, University of Tuebingen, Germany.
Agents Actions Suppl. 1992;38 ( Pt 3):311-6.
Components of the FX11-kallikrein systems were determined in blood samples from non diabetics and diabetics undergoing cardiopulmonary bypass (CPB). FX11 and prekallikrein levels fell in both groups with the largest falls in the diabetic group. Kallikrein inhibition was also lower in the diabetic group. Alpha-2-macroglobulin levels were lower in the diabetic group before operation and were markedly lower throughout CPB. Kallikrein like activities were also lower in the diabetic group. Beta FX11a inhibition values were higher in the diabetic group and fell in both groups during CPB. From the results obtained we concluded that the lower levels of FX11, prekallikrein, kallikrein inhibition and alpha-2-macroglobulin in the diabetic patients during CPB reflect enhanced activation of the FX11-plasma kallikrein systems. Blood loss in the diabetic group was higher than the for non diabetic group.
在接受体外循环（CPB）的非糖尿病患者和糖尿病患者的血样中测定了FX11-激肽释放酶系统的成分。两组患者的FX11和前激肽释放酶水平均下降，糖尿病组下降幅度最大。糖尿病组的激肽释放酶抑制作用也较低。糖尿病组术前α2-巨球蛋白水平较低，且在整个CPB过程中显著降低。糖尿病组的激肽释放酶样活性也较低。糖尿病组的βFX11a抑制值较高，且两组在CPB期间均下降。根据所得结果，我们得出结论，糖尿病患者在CPB期间FX11、前激肽释放酶、激肽释放酶抑制作用和α2-巨球蛋白水平较低，反映了FX11-血浆激肽释放酶系统的激活增强。糖尿病组的失血量高于非糖尿病组。
